RPS Diagnostics Inc.

7227 Delainey Court, 34240 Sarasota, Florida
United States of America

Telephone +1 941 5561864
Fax +1 941 5561851

This company is co-exhibitor of
U.S. Department of Commerce, U.S. Commercial Service


Hall map

MEDICA 2016 hall map (Hall 16): stand C04

Fairground map

MEDICA 2016 fairground map: Hall 16

Our range of products

Product categories

  • 03  Diagnostics
  • 03.05  Infectious Immunology
  • 03.05.08  Rapid tests - Infectious immunology

Rapid tests - Infectious immunology

Our products

Product category: Rapid tests - Infectious immunology


Acute conjunctivitis – more commonly known as “pink eye” – affects nearly 6 million people in the U.S. every year.1 Pink eye is usually caused by bacteria, viruses, or allergens.
AdenoPlus® is the first and only CLIA-waived, point-of-care test that detects all known serotypes of Adenoviral conjunctivitis.
By implementing AdenoPlus® into your practice, you can:
• Make a rapid, accurate diagnosis before the patient leaves your office
• Isolate and manage contagious patients
• Prevent the spread of infection
• Reduce unnecessary antibiotic prescriptions
• Reduce potential ocular allergies and toxicities associated with unnecessary antibiotic use
• Help prevent antibiotic resistance

More Less

About us

Company details

RPS Diagnostics is an emerging developer, manufacturer and marketer of rapid, point-of-care diagnostic tests. RPS products bridge the gap between current clinical practice and standard of care, helping physicians provide the best possible patient management while acting as good stewards of therapeutic resources. Founded in 2004, RPS’s innovative and patented technology platform facilitates the development of a spectrum of cost-effective tests to support the rapid diagnosis of patients with infectious diseases and inflammatory conditions. RPS tests have high sensitivity and specificity, and can be easily performed by a clinician or their staff without extensive training or additional equipment.

RPS has CE mark on a new and innovative product, FebriDx, for which we are seeking qualified distribution partners in Europe. Qualified distributors should have the following characteristics:

- An established business in a European country with a well-trained sales force
- Experience in selling point-of-care and infectious disease diagnostic products to physicians, pharmacists, and other customers (market-dependent) who utilize point of care tests
- Strong marketing support, including the ability to create and execute product launch plans and connect with key thought leaders in target markets

FebriDx is a rapid, point-of-care, dual-biomarker test that uses a fingerstick blood sample to help identify and differentiate a clinically significant immune response to acute respiratory infection, as well as differentiate viral from bacterial cause of infection. 

More Less

Company data

Number of employees




Area of business